Analyst Ratings For Fortress Biotech (NASDAQ:FBIO)
Today, B. Riley initiated coverage on Fortress Biotech (NASDAQ:FBIO) with a Buy with a price target of $10.00.
Some recent analyst ratings include
- 2/28/2018-B. Riley initiated coverage with a Buy rating.
- 7/11/2017-Rodman & Renshaw initiated coverage with a Buy rating.
- 7/4/2017-FBR & Co Reiterated Rating of Buy.
- 3/22/2017-JMP Securities initiated coverage with a Mkt Outperform rating.
- 10/3/2016-Roth Capital initiated coverage with a Buy rating.
Recent Insider Trading Activity For Fortress Biotech (NASDAQ:FBIO)
Fortress Biotech (NASDAQ:FBIO) has insider ownership of 33.30% and institutional ownership of 11.89%.
- On 12/14/2017 George Avgerinos, SVP, sold 12,000 with an average share price of $3.55 per share and the total transaction amounting to $42,600.00.
- On 12/12/2017 George Avgerinos, SVP, sold 25,593 with an average share price of $3.59 per share and the total transaction amounting to $91,878.87.
- On 11/6/2017 Lindsay A Md Rosenwald, CEO, bought 40,000 with an average share price of $25.00 per share and the total transaction amounting to $1,000,000.00.
- On 9/16/2016 George Avgerinos, SVP, sold 48,912 with an average share price of $2.55 per share and the total transaction amounting to $124,725.60.
- On 12/1/2014 Lucy Lu, CFO, bought 5,000 with an average share price of $1.45 per share and the total transaction amounting to $7,250.00.
- On 11/6/2014 Lindsay A Md Rosenwald, CEO, bought 150,000 with an average share price of $1.61 per share and the total transaction amounting to $241,500.00.
- On 11/6/2014 Malcolm Hoenlein, Director, bought 25,000 with an average share price of $1.61 per share and the total transaction amounting to $40,250.00.
Recent Trading Activity for Fortress Biotech (NASDAQ:FBIO)
Shares of Fortress Biotech closed the previous trading session at 4.12 up +0.07 1.62% with 4.039999961853027 shares trading hands.